Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: swisher em. medRxiv [Preprint]. 2023 Aug 28:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. medRxiv. 2023. PMID: 36993400 Free PMC article. Preprint.
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O, Swisher EM, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, Lin KK, Maloney L, Freyer G, You B. Colomban O, et al. Among authors: swisher em. EBioMedicine. 2023 Mar;89:104477. doi: 10.1016/j.ebiom.2023.104477. Epub 2023 Feb 16. EBioMedicine. 2023. PMID: 36801617 Free PMC article.
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.
Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. Duska LR, et al. Among authors: swisher em. JCO Precis Oncol. 2023 Sep;7:e2300235. doi: 10.1200/PO.23.00235. JCO Precis Oncol. 2023. PMID: 37797273 Clinical Trial.
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.
Gray HJ, Chatterjee P, Rosati R, Appleyard LR, Durenberger GJ, Diaz RL, Swan HA, Peretti D, Pollastro M, Ainge T, Kapeli K, Pereira S, Margossian AL, Banda K, Goff BA, Swisher EM, Bernard B, Kemp CJ, Grandori C. Gray HJ, et al. Among authors: swisher em. NPJ Precis Oncol. 2023 May 18;7(1):45. doi: 10.1038/s41698-023-00379-8. NPJ Precis Oncol. 2023. PMID: 37202426 Free PMC article.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Liu JF, Xiong N, Wenham RM, Wahner-Hendrickson A, Armstrong DK, Chan N, O'Malley DM, Lee JM, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye AB, Barry WT, Cheng SC, Polak M, Swisher EM, Shapiro GI, Kohn EC, Ivy SP, Matulonis UA. Liu JF, et al. Among authors: swisher em. Gynecol Oncol. 2024 May 16;187:105-112. doi: 10.1016/j.ygyno.2024.05.002. Online ahead of print. Gynecol Oncol. 2024. PMID: 38759516
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM. Giudice E, et al. Among authors: swisher em. Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6. Nat Commun. 2024. PMID: 38555285 Free PMC article. Clinical Trial.
The role of aberrant DNA methylation in cancer initiation and clinical impacts.
Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, J Wakefield M. Geissler F, et al. Among authors: swisher em. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231220511. doi: 10.1177/17588359231220511. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38293277 Free PMC article.
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J. Cecchini M, et al. Among authors: swisher em. Br J Cancer. 2024 Feb;130(3):476-482. doi: 10.1038/s41416-023-02534-1. Epub 2023 Dec 22. Br J Cancer. 2024. PMID: 38135713 Free PMC article. Clinical Trial.
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY, Vandenberg CJ, Lim R, Christie EL, Garsed DW, Lieschke E, Nesic K, Kondrashova O, Ratnayake G, Radke M, Penington JS, Carmagnac A, Heong V, Kyran EL, Zhang F, Traficante N; Australian Ovarian Cancer Study; Huang R, Dobrovic A, Swisher EM, McNally O, Kee D, Wakefield MJ, Papenfuss AT, Bowtell DDL, Barker HE, Scott CL. Ho GY, et al. Among authors: swisher em. Ther Adv Med Oncol. 2023 Nov 22;15:17588359231208674. doi: 10.1177/17588359231208674. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028140 Free PMC article.
191 results